# Olaris

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/olaris

- Industry: Healthcare
- Headquarters: Framingham, US
- Website: www.olarisbor.com/
- Latest round: Series B (Apr 8, 2025)
- Investors on record: 5

## About

Founded in 2013 and based in Massachusetts, US, Olaris, Inc operates as a precision medicine platform developer that aims to match the appropriate medicines to the right patient. In September 2019, Olaris, Inc raised an undisclosed amount from Alumni Ventures. Dr. Elizabeth O'Day is the founder and CEO of the company. The company offers a proprietary metabolite profiling platform that is aimed to deliver the treatment for each patient depending on their unique circumstances. Olaris develops in vitro diagnostics by combining metabolomics and machine learning to identify Biomarkers of Response (BoRs) to improve patient outcomes, limit side effects, and reduce waste in the healthcare system. The firm partners with Thermo Fisher Scientific, The Michael J. Fox Foundation For Parkinson’s Research (MJFF), Caraway Therapeutics, and Loulou Foundation.

## Funding rounds

- Series B, Apr 8, 2025 — Pear Tree Funds, Alumni Ventures Group, NorthPoint Capital Partners, LabCorp Ventures, Innospark Ventures
- Series B, Sep 21, 2021 — Alumni Ventures Group

## Investors

- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series B
- Pear Tree Funds (https://capitalatlas.ai/funds/pear-tree-funds) — Series B
- NorthPoint Capital Partners (https://capitalatlas.ai/funds/northpoint-capital-partners) — Series B
- LabCorp Ventures (https://capitalatlas.ai/funds/labcorp-ventures) — Series B
- Innospark Ventures (https://capitalatlas.ai/funds/innospark-ventures) — Series B